Bruni, B, Carlini, M, Gamba, S, Giobbe, D, Nobili, M.
Catatonia with high CSF lactate in a case of diabetes with associated conditions. Acta Diabetol Lat
1980; 17: 273–6.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM-IV-TR). APA, 2000.
Suzuki, H, Fukushima, T, Makino, K, Kuwabara, T.
Patient with encephalitis presenting with olanzapine-responsive malignant catatonia [in Japanese]. Rinsho Shinkeigaku
2010; 50: 329–31.
Dalò, V, Lavatelli, L, Zeppegno, P, Torre, E.
Catatonia: a case report. Eur Psychiatry
2010; 25 (suppl 1): 1163.
Kaufmann, RM, Schreinzer, D, Strnad, A, Mossaheb, N, Kasper, S, Frey, R.
Case report: intestinal atonia as an unusual symptom of malignant catatonia responsive to electroconvulsive therapy. Schizopr Res
2006; 84: 178–9.
Narayanaswamy, JC, Tibrewal, P, Zutshi, A, Srinivasaraju, R, Math, SB. Clinical predictors of response to treatment in catatonia. Gen Hosp Psychiatry
2012; 34: 312–4.
Rosebush, PI, Mazurek, MF. Catatonia and its treatment. Schizophr Bull
2010; 36: 239–42.
Ungvari, GS, Chiu, HFK, Chow, LY, Lau, BST, Tang, WK. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology
1999; 142: 393–8.
Kaestner, F, Mostert, C, Behnken, A, Boeckermann, I, Ternes, F, Diedrich, M, et al. Therapeutic strategies for catatonia in paraneoplastic encephalitis. World J Biol Psychiatry
2008; 9: 236–40.
Bhati, MT, Datto, CJ, O'Reardon, JP. Clinical manifestations, diagnosis, and empirical treatments for catatonia. Psychiatry (Edgmont)
2007; 4: 46–52.
Rohland, BM, Carroll, BT, Jacoby, RG. ECT in the treatment of the catatonic syndrome. J Affect Disord
1993; 29: 255–61.
Malur, C, Pasol, E, Francis, A.
ECT for prolonged catatonia. J ECT
2001; 17: 55–9.
Maletzky, BM. The first-line use of electroconvulsive therapy in major affective disorders. J ECT
2004; 20: 112–7.
Catatonia and ECT: Meduna's biological antagonism hypothesis reconsidered. World J Biol Psychiatry
2002; 3: 105–8.
White, DA, Robins, AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry
1991; 158: 419–21.
Lee, JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry
1998; 44: 499–507.
Fink, M, Taylor, MA. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog Neuropsychopharmacol Biol Psychiatry
2006; 30: 1182–3.
Hung, YY, Yang, PS, Huang, TL. Clozapine in schizophrenia patients with recurrent catatonia: report of two cases. Psychiatry Clin Neurosci
2006; 60: 256–8.
Guzman, CS, Myung, VH, Wang, YP. Treatment of periodic catatonia with olanzapine: a case report. Rev Bras Psiquiatr
2007; 29: 380.
Hervey, WM, Stewart, JT, Catalano, G.
Treatment of catatonia with amantadine. Clin Neuropharmacol
2012; 35: 86–7.
Rosebush, PI, Hildebrand, AM, Furlong, BG, Mazurek, MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry
1990; 51: 357–62.
ten Have, M, Vollebergh, W, Bijl, R, Nolen, WA. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord
2002; 68: 203–13.
De Zelicourt, M, Dardennes, R, Verdoux, H, Gandhi, G, Khoshnood, B, Chomette, E, et al. Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France. Pharmacoeconomics
2003; 21: 1080–90.
Taylor, MA, Abrams, R.
Catatonia: prevalence and importance in the manic phase of manic-depressive illness. Arch Gen Psychiatry
1977; 34: 1223–5.